GLUE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GLUE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Monte Rosa Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $152.52 Mil. Monte Rosa Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was $266.75 Mil. Therefore, Monte Rosa Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.57.
The historical rank and industry rank for Monte Rosa Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 5 years, the highest Equity to Asset Ratio of Monte Rosa Therapeutics was 0.97. The lowest was -1.10. And the median was 0.79.
The historical data trend for Monte Rosa Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Equity-to-Asset | -1.10 | -0.99 | 0.95 | 0.79 | 0.59 |
Monte Rosa Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.79 | 0.77 | 0.73 | 0.59 | 0.57 |
For the Biotechnology subindustry, Monte Rosa Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Monte Rosa Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Monte Rosa Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 179.25 | / | 303.755 | |
= |
Monte Rosa Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as
Equity to Asset (Q: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 152.519 | / | 266.746 | |
= | 0.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monte Rosa Therapeutics (NAS:GLUE) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Monte Rosa Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Edmund Dunn | officer: Principal Accounting Officer | MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON MA 02210 |
Anthony M. Manning | director | C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Jan Skvarka | director | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Philip Nickson | officer: General Counsel | MONTE ROSA THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135 |
Julian G Jones | officer: Chief Business Officer | MONTE ROSA THERAPEUTICS, INC., 645 SUMMER STREET, SUITE 102, BOSTON MA 02210 |
Peter W. Sonsini | 10 percent owner | 2855 SAND HILL ROAD, MENLO PARK CA 94025 |
Cormorant Asset Management, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Paul Edward Walker | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Edward T Mathers | 10 percent owner | C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Kimberly Blackwell | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Cormorant Private Healthcare Fund Ii, Lp | 10 percent owner | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
New Enterprise Associates 17, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Nea Partners 17, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-30-2022
By GuruFocusNews GuruFocusNews • 06-10-2022
By Value_Insider Value_Insider • 11-10-2022
By sperokesalga sperokesalga • 04-17-2023
By Marketwired • 10-17-2023
By GuruFocusNews GuruFocusNews • 02-03-2022
By Stock market mentor Stock market mentor • 02-03-2023
By GuruFocusNews GuruFocusNews • 03-29-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
By GuruFocusNews GuruFocusNews • 05-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.